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A central observation about the US health-
care sector is the existence of substantial dif-
ferences in productivity across regions and 
across hospitals. Annual Medicare spending per 
capita ranges from $6,200 to $16,300 across 
geographic areas, yet health outcomes do not 
positively covary with these spending differ-
entials; similar patterns have been documented 
across hospitals within geographic markets (Skinner 2011). This has generated volumi-
nous academic research trying to understand the 
root causes of productivity dispersion and what 
can increase productivity at  underperforming 
hospitals (e.g., Skinner and Staiger 2009; 
Finkelstein, Gentzkow, and Williams 2014). 
These Dartmouth Atlas facts have also attracted 
considerable popular attention (e.g., Gawande 
2009), and were heavily cited during the dis-
cussions around the Affordable Care Act (e.g., 
Office of Management and Budget 2009).1
Both academic and policy discussions of 
productivity dispersion in healthcare typi-
cally ignore the  well-documented existence of 
1 These can be found at http://www.dartmouthatlas.org.
 enormous productivity dispersion within man-
ufacturing industries as well. For example, on 
average within US manufacturing industries, 
the ninetieth productivity percentile plant cre-
ates almost twice as much output as the tenth 
 percentile plant, given the same inputs; this dis-
persion likewise exists within and across geo-
graphic markets (Syverson 2011).
We estimate the extent of productivity dis-
persion across US hospitals in treating heart 
attacks2 and compare it to productivity dis-
persion within US manufacturing industries. 
Measuring productivity is notoriously difficult, 
and  cross-industry comparisons are notoriously 
difficult to interpret. These important caveats 
notwithstanding, our basic finding is striking 
and, we believe, surprising.
We estimate that productivity dispersion 
across hospitals in treating heart attacks is quan-
titatively similar to or slightly smaller than pro-
ductivity dispersion within  narrowly-defined 
manufacturing industries. Figure 1 provides one 
illustrative example (we discuss more compari-
sons below), looking at productivity dispersion 
in  ready-mixed concrete, which, like healthcare, 
is produced and consumed locally; Figure 1 
shows slightly lower productivity dispersion 
in heart attack treatment across hospitals than 
across  ready-mixed concrete plants.
I. Empirical Approach
A. Setting, Data, and Estimation
We estimate hospital productivity (TFP) in 
the treatment of heart attacks (also known as 
acute myocardial infarctions or AMI). We focus 
on heart attacks for several reasons, including 
their importance as a cause of death and the 
broad agreement that survival—which we can 
measure well—is the key output.
2 We provided substantially more detail on estimation and 
results in our earlier working paper (Chandra et al. 2013). 
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We posit a  patient-level log health production 
function:
(1)  ln ( y p ) = ln ( A h,t ) + μ  ∑ 
k
  α k ln ( R p,k ) 
 + μ ln ( x p ) +  ε p ,
where output  ( y p ) is survival of patient p treated 
at hospital h in year t,  x p is a measure of hospital 
inputs used to treat this patient, and  R p,k is a vec-
tor of k observable,  patient-level factors (“risk 
adjustors”). The parameter µ is the elasticity 
of survival days with respect to  risk-adjusted 
inputs. Our key focus is on ln( A h,t ), which mea-
sures total factor productivity (TFP) of hospital 
h in year t; empirically, our TFP estimates are 
the coefficients on a set of  hospital-year fixed 
effects.
Our data are a census of Medicare Part A (i.e., 
inpatient hospital) claims for AMI Medicare 
patients from 1993–2007. We exclude patients 
who have had an admission for an AMI in the 
prior year and  hospital-years with fewer than five 
AMI patients. Our data consist of about 3.5 mil-
lion AMI patients, ages 66 and over, in 55,540 
 hospital-years and 5,346 unique hospitals.
B. Estimation Challenges
In any setting, estimating productivity is 
conceptually straightforward but practically 
challenging (Syverson 2011). Hospital produc-
tivity is no exception; it avoids some  well-known 
issues (for example we can measure output 
directly rather than relying on revenue proxies 
for output) but also generates new ones (such as 
potential heterogeneity across hospitals in their 
patients’ baseline survival rates).
Our baseline output measure ( y p ) is the num-
ber of days that the patient survives after receiv-
ing initial treatment, up through the first year; 
it is bounded from below at 1 and above at 367 
days. About  two-thirds of our sample survives 
past one year; average survival days through one 
year, censoring anyone who survives more than 
one year at 367 days of survival, is 268 days (standard deviation = 149). Our findings are 
robust to measuring survival over shorter (e.g., 
30 days) or longer (e.g., five year) windows.
Input measurement poses a key challenge for 
productivity estimation. We experimented with 
a variety of approaches—none of which is per-
fect—and are reassured that our productivity 
dispersion findings are robust across them. Our 
baseline input measure is a single input index of 
the ( dollar-converted) sum of  diagnostic-related 
group (or DRG) weights during the first 30 
days following a heart attack. DRG weights 
reflect the Centers for Medicare and Medicaid 
Services’ (CMS) assessment of the resources 
necessary to treat a patient in a given DRG. On 
average, about $16,000 worth of hospital inputs 
are used in the treatment of patients in this study 
in the 30 days following a heart attack, with a 
standard deviation of about $12,000. Our results 
are similar if we instead measure inputs over the 
first seven days or first year following the heart 
attack.
Our input measure, while standard in the lit-
erature, carries the caveat that it does not reflect 
actual inputs used but rather  CMS-defined 
expected inputs based on the patient’s diagno-
sis and broadly defined treatment approach. 
Alternatively, we measured inputs by the spe-
cific, detailed procedures performed and length 
of stay in the hospital in a  multi-input pro-
duction function; we also explored including 
 non-hospital inputs for the patient (e.g., out-
patient services), or defining inputs based on 
Medicare spending on the patient. Our findings 
are generally robust to the input measurement 
approach.
In a typical setting, productivity is the resid-
ual in a  firm-level regression of outputs on 
inputs; therefore, estimates of the scale param-
eter  μ in equation (1) may be biased by a cor-
relation between input choice and the residual (productivity). In our setting, however, because 
we observe production at the unit (patient) level, 
Figure 1. Productivity Distribution Across Hospitals 
and Across Manufacturers
Note: Figure shows the fitted normal density approximation 
of the national, within-year productivity distribution for hos-
pitals treating AMI patients and for concrete plants.
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we can include  hospital-year fixed effects, esti-
mating  μ solely from  within-hospital-year vari-
ation. However, our estimate of  μ will be biased 
if, within  hospital-year, hospitals choose dif-
ferent observable input levels for patients who 
differ unobservably in their latent survival, or if 
their choice of unobservable inputs is correlated 
with observed inputs. We are therefore reas-
sured that our results are similar if we impose, 
rather than estimate, various values for μ, in an 
 index-number, or Solow residual, approach to 
measuring productivity.
Because patients are inherently heteroge-
neous, survival may depend on patient charac-
teristics, which may be correlated with input 
choices; the marginal effect of inputs on sur-
vival may also vary with patient characteristics. 
To capture both of these effects, we follow the 
standard approach in the literature and include 
controls for patient health ( R p,k ). Our baseline 
specification includes a full set of interactions 
between age, gender, and race, as well as indi-
cator variables for whether the patient has been 
admitted to the hospital in the previous year 
with any of 17 different  co-morbidities. Our 
main results are not sensitive to using fewer or 
more (for a subsample of patients where they are 
available) risk adjusters.
Finally, we apply the standard empirical 
Bayes shrinkage techniques to address potential 
 over-dispersion of our TFP estimates.
II. Results
As a “reality check” on our TFP estimates (the  hospital-year fixed effects from equation (1)), we verified that they correlate positively 
in the  cross-section with observable and inde-
pendently gathered hospital quality measures, 
such as  publicly-reported CMS measures of the 
hospital’s conformance with established clinical 
guidelines for AMI care like administering beta 
blockers and the Bloom et al. (2012) measure of 
hospital management quality.3
We estimate an average  within-year stan-
dard deviation of national hospital productivity 
for AMI treatment of 0.17; the  90–10 range is 
0.44 and the interquartile range is 0.23. In other 
words, an AMI patient treated at a ninetieth per-
3 We are extremely grateful to Nick Bloom for providing 
us with these measures. 
centile productivity hospital is expected to sur-
vive more than 1.55 times ( e 0.44 = 1.55) longer 
than had the patient been treated in the same 
manner at a tenth percentile hospital.
Figure 1 shows productivity dispersion for 
 ready-mixed concrete (standard  deviation = 0.25).4 Like healthcare, concrete is consumed 
and produced locally, so that spatial differentia-
tion (i.e., physical distance) can be an important 
barrier to competition; however, concrete is less 
differentiated than AMI treatment, insurance 
does not dampen price sensitivity, consumers 
are likely well informed about their choices, and 
prices aren’t set administratively.
Estimates of productivity dispersion in 
other US manufacturing industries also tend 
to be slightly larger than our estimates for 
healthcare. Looking across a large number of 
 narrowly-defined US manufacturing indus-
tries, researchers have estimated an average 
 within-industry standard deviation of productiv-
ity of 0.22 (Foster, Haltiwanger, and Syverson 
2008) and 0.39 (Bartelsman, Haltiwanger, and 
Scarpetta 2013), and an interquartile range of 
0.29 (Syverson  2004a). As we describe in more 
detail in Chandra et al. (2013), the more lim-
ited work on productivity dispersion in service 
industries finds dispersion that is roughly simi-
lar to manufacturing.
III. Discussion
At a broad level, our results seem at odds 
with the conventional wisdom that variation in 
healthcare productivity is due to idiosyncratic 
features of the healthcare sector, such as the lack 
of consumer information on hospital quality, the 
lack of price sensitivity by generously insured 
consumers, and the absence of market-set prices 
in favor of public sector reimbursement. More 
speculatively, they suggest that the health-
care sector may not be greatly more insulated 
against  demand-side competitive pressures than 
other sectors, as productivity dispersion has 
been shown, both theoretically and empirically, 
to shrink with greater competition within and 
across industries (e.g., Syverson 2004a, b).
4 We estimate productivity dispersion in concrete using 
data from  1972–1997 from the Census of Manufactures; 
our estimation approach (details of which are provided 
in Chandra et al. 2013) closely follows that in Foster, 
Haltiwanger, and Syverson (2008). 
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Naturally, however, there are real concerns (albeit without a clear sense as to the direction 
in which they might affect our estimates) in 
inferring the extent of  demand-side competition 
in healthcare compared to manufacturing from 
comparisons of productivity dispersion in the 
two sectors. There are important comparability 
differences in the measurement of productiv-
ity—such as differences in the output definition (survival versus revenue) and how inputs are 
measured. For instance, to directly compare the 
productivity dispersion metrics above, one has 
to view a given percentage variation in days sur-
vived after a heart attack as quantitatively anal-
ogous to the same percentage variation in tons 
of  ready-mixed concrete. Moreover, a variety of 
factors—of which competitive pressure is only 
one—may serve to reduce equilibrium produc-
tivity dispersion in a given sector. Finally, our 
analysis here is limited to one specific health-
care condition (AMI).
In related work (Chandra et al. 2015), we pres-
ent additional, complementary evidence suggest-
ing that the healthcare sector may be subject to 
standard  demand-side competitive forces. There, 
we look at four different conditions—AMI, con-
gestive heart failure, pneumonia, and hip and 
knee replacements—that together account for 
almost  one-fifth of Medicare hospital admissions 
and hospital spending. We ask whether higher 
quality hospitals attract greater market share at a 
point in time, and whether they grow more over 
time. A relationship between productivity and 
market share has been analyzed extensively in 
a variety of industries and countries as a proxy 
for the role of competition in these settings; 
intuitively, competitive forces exert pressure on 
lower productivity firms, causing them to either 
become more efficient, shrink, or exit.
We find robust evidence of market 
 reallocation to higher quality hospitals across 
clinical  outcomes-based hospital performance 
measures (survival and readmission) and 
 process-of-care-based measures (i.e., adher-
ence to  well-established practice guidelines). 
Importantly, this positive correlation between 
quality and market share is systematically and 
substantially stronger for patients with the same 
condition who have more scope for choice (i.e., 
patients who are transfers from other hospitals 
rather than arrivals via the emergency room).
Our combined results suggest that, contrary to 
the long tradition of “healthcare  exceptionalism” 
in health economics, the healthcare sector may 
have more in common with “traditional” sec-
tors subject to standard market forces than 
is often assumed. Of course, a given amount 
of  productivity variation or a given level of 
 allocation to higher quality producers may 
be more greatly valued in healthcare than in 
manufacturing, not to mention of greater con-
sequence for public sector budgets. It is argu-
ably these features of healthcare that make it 
exceptional.
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